35 Top Revenue Generating Cannabis Stocks Ranked as of November 15th

The Public Cannabis Company Revenue Tracker, managed by New Cannabis Ventures, ranks the top revenue producing cannabis stocks that generate industry sales of more than US$2.5 million per quarter. This data-driven, fact-based tracker will continually update based on new filings so that readers can stay up to date. Companies must file with the SEC or SEDAR to be considered for inclusion.

35 companies currently qualify for inclusion, with 21 filing in U.S dollars and 14 in the Canadian currency. Since our last report, we added Curaleaf (CSE: CURA) (OTC: LDVTF), Halo Labs (NEX: HALO) (OTC: AGEEF), Harvest Health & Recreation (CSE: HARV), Helix TCS (OTC: HLIX), Medicine Man Technologies (OTC: MDCL), Newstrike Brands (TSXV: HIP) (OTC: NWKRF) and Surna (OTC: SRNA). We note that Elixinol Global (ASX: EXL) (OTC: ELLXF) can’t be included at this time despite its likely qualification, as the company’s Q3 report didn’t break out the sales of CBD. Similarly, the Acreage Holdings (CSE: ACRG) Filing Statement included only year-to-date financials and not a quarterly number for revenue. We expect to be adding several additional companies, including Acreage Holdings, over the balance of 2018 as existing public companies continue to ramp up sales and as others begin to trade publicly.

CV Sciences (OTC: CVSI),  Golden Leaf Holdings (CSE: GLH) (OTC: GLDFF), GrowGeneration (OTC: GRWG), Halo Labs, Helix TCS, Innovative Industrial Properties (NYSE: IIPR), Marimed (OTC: MRMD), Medicine Man Technologies, Planet 13 (CSE: PLTH) (OTC: PLNHF), Surna, Terra Tech (OTC: TRTC) and Tilray (NASDAQ: TLRY) have all provided Q3 results in the first half of November. Those reporting revenue in excess of $10 million included CV Sciences, which saw 143% growth and positive adjusted EBITDA, and Tilray, which saw sales growth of 86% while generating a large operating loss.

Over the balance of November, we will get reports from seven companies, including KushCo Holdings (OTC: KSHB), which pre-announced its Q4 sales at about $19 million in September, which would represent 120% growth from year-ago sales, is expected to file by the end of November, along with six others, including Charlotte’s Web (CSE: CWEB) (OTC: CWBHF), Curaleaf, Green Thumb Industries (CSE: GTII) (OTC: GTBIF), Harvest Health & Recreation, MedMen Enterprises (CSE: MMEN) (OTC: MMNFF) and Trulieve (CSE: TRUL) (OTC: TCNNF), each of which will file quarterly reports. These six companies reported a combined $99.8 million revenue in the June quarter, all with growth rates in excess of 90%. Several have already scheduled conference calls to discuss the quarterly results.

Of the companies that report in Canadian dollars, Aurora Cannabis (TSX: ACB) (NYSE: ACB), CannTrust (TSX: TRST) (OTC: CNTTF), Canopy Growth (TSX: WEED) (NYSE: CGC), Cronos Group (TSX: CRON) (NASDAQ: CRON),  Newstrike Brands and Supreme Cannabis (TSXV: FIRE) (OTC:  SPRWF) all reported quarterly updates, with Aurora Cannabis moving to the top following the acquisition of MedReleaf, which was included partially in the quarter. Canopy Growth FY19-Q2 sales were below the prior quarter’s revenue.

Of the companies that report in Canadian dollars, we expect five issue financial reports in the second half of November, including 1933 Industries (CSE: TGIF) (OTC: TGIFF), Isodiol International (CSE: ISOL) (OTC: ISOLF),  MPX Bioceutical (CSE: MPX) (OTC: MPXEF), Origin House (CSE: OH) (OTC: ORHOF), which was formerly CannaRoyalty, and Sunniva (CSE: SNN) (OTC: SNNVF).

Visit the Public Cannabis Company Revenue Tracker to track and explore the complete list of qualifying companies.

Exclusive article by Alan Brochstein, CFA
Alan Brochstein, CFA
Based in Houston, Alan leverages his experience as founder of online community 420 Investor, the first and still largest due diligence platform focused on the publicly-traded stocks in the cannabis industry. With his extensive network in the cannabis community, Alan continues to find new ways to connect the industry and facilitate its sustainable growth. At New Cannabis Ventures, he is responsible for content development and strategic alliances. Before shifting his focus to the cannabis industry in early 2013, Alan, who began his career on Wall Street in 1986, worked as an independent research analyst following over two decades in research and portfolio management. A prolific writer, with over 650 articles published since 2007 at Seeking Alpha, where he has 70,000 followers, Alan is a frequent speaker at industry conferences and a frequent source to the media, including the NY Times, the Wall Street Journal, Fox Business, and Bloomberg TV. Contact Alan: Twitter | Facebook | LinkedIn | Email

Get Our Sunday Newsletter